• HATU for Peptide Synthesis: Workflow & Troubleshooting

  2026-09-07

  HATU enables rapid carboxylic acid activation for demanding peptide synthesis chemistry, small-molecule inhibitor assembly, and selected esterifications. This practical guide connects peptide coupling with DIPEA to assay-ready medicinal chemistry workflows, including parameter selection, workup, and troubleshooting.

• Sodium Salicylate in Stromal Signaling Research

  2026-09-07

  A translational perspective on using sodium salicylate as an NF-κB inhibitor to interrogate inflammatory and oxidative-stress biology alongside emerging strategies for pancreatic tumor-stroma remodeling.

• Rosemary Extract and Renal Amyloidosis Mechanisms

  2026-09-05

  This study integrates amyloid-fibril biophysics, renal cell models, and mouse pathology to examine how rosemary ethanol extract may counter renal amyloidosis. Its findings connect fibril disruption with calcium and reactive oxygen species control, suppression of PERK/ATF-4/CHOP endoplasmic reticulum stress, and reduced apoptosis, while also highlighting the limits of translating extract-based evidence into therapy.

• DiscoveryProbe Stem Cell Compound Library Plus Workflow

  2026-09-05

  DiscoveryProbe™ Stem Cell Compound Library Plus turns broad pathway coverage into a practical workflow for phenotypic screening, differentiation studies, and mechanism-guided validation. Its strongest use case is pairing high-content imaging with viability, lineage, and target-proximal assays so researchers can distinguish meaningful cell-state changes from nonspecific toxicity.

• NEDD4L, PRMT5, and CRC Liver Metastasis

  2026-09-04

  The reference study uses an in vivo E3-ligase screen to identify NEDD4L as a suppressor of colorectal cancer liver metastasis. Its mechanistic model connects NEDD4L-dependent PRMT5 degradation with reduced AKT1 arginine methylation and inhibition of AKT/mTOR signaling, providing a framework for studying metastatic colonization.

• Gemcitabine HCl: From DNA Damage to MRI

  2026-09-04

  Gemcitabine HCl research is strongest when molecular cytotoxicity and longitudinal tumor imaging are interpreted together. This article presents a decision-focused framework linking DNA replication inhibition, apoptosis, and multianimal MRI in pancreatic cancer models.

• T0070907: A Practical PPARγ Antagonist Guide

  2026-09-03

  T0070907 is a nanomolar PPARγ antagonist for separating receptor-dependent transcription from downstream phenotypes. This guide connects assay design, adipogenesis inhibition, PPARγ/RXRα heterodimer modulation, and cancer-cell-cycle workflows with practical controls and troubleshooting.

• Cyclopamine: From Hedgehog Mechanism to Translation

  2026-09-02

  A translational framework for using Cyclopamine to interrogate Smoothened-dependent biology, validate tumor responses, manage developmental risk, and connect pathway perturbation with emerging insights into inflammatory gene regulation.

• Dual-Action Inhibitors and p38α Dephosphorylation

  2026-09-02

  A 2024 preprint shows that selected kinase inhibitors can do more than occupy the p38α active site: they can also accelerate WIP1-mediated removal of the activation-loop phosphate. Structural and biochemical results support a conformation-directed model that may improve interpretation of p38 inhibition experiments, while leaving compound- and cell-specific validation essential.

• Epalrestat: Designing Polyol-Pathway Assays

  2026-09-01

  Epalrestat is an aldose reductase inhibitor that enables more precise studies of glucose-to-fructose flux, redox stress, and disease phenotypes. This article presents an assay-centered framework linking polyol pathway inhibition with diabetic neuropathy research, oxidative stress research, Parkinson’s disease models, and emerging cancer-metabolism questions.

• Isochlorogenic Acid A Hydrogel for Wound Repair

  2026-09-01

  A 2026 study developed an amylopectin/carboxymethyl chitosan hydrogel containing Isochlorogenic acid A/Fe(III) co-assembled nanoparticles to address the compound’s solubility and stability constraints in infected wound repair. The composite combined antibacterial activity, favorable physical properties, enhanced cell migration, and improved healing-associated inflammatory and vascularization markers in vitro and in vivo.

• How ARBs Reprogram Cold Tumors for Checkpoint Therapy

  2026-08-31

  The reference study identifies AGTR1 as a stromal vulnerability in collagen-rich, immune-excluded “armored and cold” tumors and shows that angiotensin receptor blockade can improve immune checkpoint blockade responses. Its key contribution is linking AT1-axis inhibition in cancer-associated fibroblasts to reduced collagen production, tumor-microenvironment remodeling, and clinical response patterns across cohorts.

• Mycophenolic acid: Reliable Cell Assay Design

  2026-08-31

  Learn how Mycophenolic acid, SKU B1981, can improve the interpretation and reproducibility of cell viability, proliferation, and immunometabolism assays. This scenario-based guide covers solvent handling, protocol optimization, data interpretation, and practical vendor selection.

• Pentoxifylline Workflows for Inflammation Research

  2026-08-30

  Pentoxifylline combines phosphodiesterase inhibition with practical utility across LPS-driven inflammation, neonatal sepsis models, psoriasis research, and sperm-motility assays. This workflow-focused guide covers concentration selection, TLR4-centered readouts, cross-domain applications, and troubleshooting for more reproducible experiments.

• Deracoxib in COX-2 Inflammation Assays

  2026-08-29

  Deracoxib is a selective COX-2 inhibitor that can help separate prostaglandin-driven effects from broader inflammatory signaling. This guide builds an assay strategy around orthogonal readouts, viability controls, and insights from a poly(I:C)-macrophage study.

8013 records 1/535 page Next 12345 下5页 Last page